0
Upcoming Allied Market Research
2023
Drug Repurposing Market

Drug Repurposing Market

by Therapeutic Area (Oncology, CNS Disorders, Neurodegenerative Diseases, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

Report Code: A06185
Nov 2023 | Pages: NA
Tables: NA
Charts: NA
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Drug Repurposing Market

Request Now !

Drug repurposing, also known as drug repositioning is an approach to identify a novel medical indication for a drug. It may involve identification of a novel clinical use for an existing drug approved for a different indication or even finding clinical use for any unapproved drug. It has many advantages over traditional de novo drug discovery approaches, such as significant reduction of the cost and development time for the drug purposing. Drug repurposing is based on polypharmacology, complex diseases such as cancers and neurodegenerative diseases that involve networks of multiple genes, hence require multiple pharmacophores and system biology-based approaches for their therapeutic application. Advances in computation power and field of computational biology, has brought up various opportunitiesto find new treatments for rare diseases using existing compounds. Many academic research groups and startup companies are actively partaking in drug repurposing. Many pharmaceutical companies have formed partnerships with many of these organizations to help facilitate repurposing oftheir existing products. For instance, in 2016,Sanofi S.A. (Sanofi Genzyme) signed a research agreement with Recursion Pharmaceuticals, LLC to identify new uses for Sanofi’s clinical stage molecules formany genetic diseases. Likewise, Astellas Pharma Inc. also has partnered with Biovista Inc., and NuMedii, Inc. for drug repurposing.

The global drug repurposing market experiences growth due to shorter drug development time for repurposed drugs compared to new chemical entities. In addition, advances in the computational power to process large databases has allowed cost-effective solutions to approach drug development. This further drives the growth of the market. However, limited understanding of polypharmaco logical effects of drugs and lack of trained personnel restrains the growth of the market. In contrast, increase in partnership of pharmaceutical companies among various academic research groups and startups to facilitate drug repurposing activities is anticipated to provide lucrative opportunities for the growth of the market.

The drug repurposing market is segmented on the basis of therapeutic area. By therapeutic area, the market is segmented intooncology, CNS disorders, neurodegenerative diseases, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The report provides a comprehensive analysis of the key players of the drug repurposing market including Atomwise, Inc., Biovista, Inc., Centene Corporation (Health Net, LLC)NuMedii, Inc., Recursion Pharmaceuticals, Inc., SOM Innovation Biotech, S.L., Sosei Group Corporation (SoseiHeptares), Exscientia Limited, and Healx. Other players in the clue chain include Pfizer Inc., Johnson & Johnson, Sanofi, Astellas Pharma, GlaxoSmithKline plc, and others.

Key Benefits For Stakeholders

  • This report provides a detailed quantitative analysis of the current drug repurposing market trends and futureestimations which assists to identify the prevailing drug repurposing market opportunities. 

  • An in-depth market analysis includes various countries, and is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate country-specific plans.

  • A comprehensive analysis of the factors that drives and restrains the growth of the global drug repurposing market is provided.

  • Region-wise market conditions are comprehensively analyzed in this report.

  • An extensive analysis of various countries provides insights that are expected to allow companies to strategically plan their business moves.

  • Key market players within the drug repurposing market are profiled in this report and their strategies are analyzed thoroughly, which help to understand the competitive outlook of the market.  

Drug Repurposing Market Report Highlights

Aspects Details
By Therapeutic Area
  • Oncology
  • CNS Disorders
  • Neurodegenerative Diseases
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Recursion Pharmaceuticals Inc., Centene Corporation (Health Net LLC), Exscientia Limited, Biovista Inc., Healx, Sosei Group Corporation (SoseiHeptares), NuMedii Inc., Atomwise Inc., SOM Innovation Biotech S.L.
 
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Therapeutic Area

    • 4.2. Oncology

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. CNS Disorders

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Neurodegenerative Diseases

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Others

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: DRUG REPURPOSING MARKET, BY REGION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Region

    • 5.2. North America

      • 5.2.1. Key Market Trends and Opportunities

      • 5.2.2. Market Size and Forecast, By Therapeutic Area

      • 5.2.3. Market Size and Forecast, By Country

      • 5.2.4. U.S. Drug Repurposing Market

        • 5.2.4.1. Market Size and Forecast, By Therapeutic Area
      • 5.2.5. Canada Drug Repurposing Market

        • 5.2.5.1. Market Size and Forecast, By Therapeutic Area
      • 5.2.6. Mexico Drug Repurposing Market

        • 5.2.6.1. Market Size and Forecast, By Therapeutic Area
    • 5.3. Europe

      • 5.3.1. Key Market Trends and Opportunities

      • 5.3.2. Market Size and Forecast, By Therapeutic Area

      • 5.3.3. Market Size and Forecast, By Country

      • 5.3.4. France Drug Repurposing Market

        • 5.3.4.1. Market Size and Forecast, By Therapeutic Area
      • 5.3.5. Germany Drug Repurposing Market

        • 5.3.5.1. Market Size and Forecast, By Therapeutic Area
      • 5.3.6. Italy Drug Repurposing Market

        • 5.3.6.1. Market Size and Forecast, By Therapeutic Area
      • 5.3.7. Spain Drug Repurposing Market

        • 5.3.7.1. Market Size and Forecast, By Therapeutic Area
      • 5.3.8. UK Drug Repurposing Market

        • 5.3.8.1. Market Size and Forecast, By Therapeutic Area
      • 5.3.9. Russia Drug Repurposing Market

        • 5.3.9.1. Market Size and Forecast, By Therapeutic Area
      • 5.3.10. Rest Of Europe Drug Repurposing Market

        • 5.3.10.1. Market Size and Forecast, By Therapeutic Area
    • 5.4. Asia-Pacific

      • 5.4.1. Key Market Trends and Opportunities

      • 5.4.2. Market Size and Forecast, By Therapeutic Area

      • 5.4.3. Market Size and Forecast, By Country

      • 5.4.4. China Drug Repurposing Market

        • 5.4.4.1. Market Size and Forecast, By Therapeutic Area
      • 5.4.5. Japan Drug Repurposing Market

        • 5.4.5.1. Market Size and Forecast, By Therapeutic Area
      • 5.4.6. India Drug Repurposing Market

        • 5.4.6.1. Market Size and Forecast, By Therapeutic Area
      • 5.4.7. South Korea Drug Repurposing Market

        • 5.4.7.1. Market Size and Forecast, By Therapeutic Area
      • 5.4.8. Australia Drug Repurposing Market

        • 5.4.8.1. Market Size and Forecast, By Therapeutic Area
      • 5.4.9. Thailand Drug Repurposing Market

        • 5.4.9.1. Market Size and Forecast, By Therapeutic Area
      • 5.4.10. Malaysia Drug Repurposing Market

        • 5.4.10.1. Market Size and Forecast, By Therapeutic Area
      • 5.4.11. Indonesia Drug Repurposing Market

        • 5.4.11.1. Market Size and Forecast, By Therapeutic Area
      • 5.4.12. Rest of Asia Pacific Drug Repurposing Market

        • 5.4.12.1. Market Size and Forecast, By Therapeutic Area
    • 5.5. LAMEA

      • 5.5.1. Key Market Trends and Opportunities

      • 5.5.2. Market Size and Forecast, By Therapeutic Area

      • 5.5.3. Market Size and Forecast, By Country

      • 5.5.4. Brazil Drug Repurposing Market

        • 5.5.4.1. Market Size and Forecast, By Therapeutic Area
      • 5.5.5. South Africa Drug Repurposing Market

        • 5.5.5.1. Market Size and Forecast, By Therapeutic Area
      • 5.5.6. Saudi Arabia Drug Repurposing Market

        • 5.5.6.1. Market Size and Forecast, By Therapeutic Area
      • 5.5.7. UAE Drug Repurposing Market

        • 5.5.7.1. Market Size and Forecast, By Therapeutic Area
      • 5.5.8. Argentina Drug Repurposing Market

        • 5.5.8.1. Market Size and Forecast, By Therapeutic Area
      • 5.5.9. Rest of LAMEA Drug Repurposing Market

        • 5.5.9.1. Market Size and Forecast, By Therapeutic Area
  • CHAPTER 6: COMPETITIVE LANDSCAPE

    • 6.1. Introduction

    • 6.2. Top Winning Strategies

    • 6.3. Product Mapping Of Top 10 Player

    • 6.4. Competitive Dashboard

    • 6.5. Competitive Heatmap

    • 6.6. Top Player Positioning,2022

  • CHAPTER 7: COMPANY PROFILES

    • 7.1. Atomwise Inc.

      • 7.1.1. Company Overview

      • 7.1.2. Key Executives

      • 7.1.3. Company Snapshot

      • 7.1.4. Operating Business Segments

      • 7.1.5. Product Portfolio

      • 7.1.6. Business Performance

      • 7.1.7. Key Strategic Moves and Developments

    • 7.2. Biovista Inc.

      • 7.2.1. Company Overview

      • 7.2.2. Key Executives

      • 7.2.3. Company Snapshot

      • 7.2.4. Operating Business Segments

      • 7.2.5. Product Portfolio

      • 7.2.6. Business Performance

      • 7.2.7. Key Strategic Moves and Developments

    • 7.3. Centene Corporation (Health Net LLC)

      • 7.3.1. Company Overview

      • 7.3.2. Key Executives

      • 7.3.3. Company Snapshot

      • 7.3.4. Operating Business Segments

      • 7.3.5. Product Portfolio

      • 7.3.6. Business Performance

      • 7.3.7. Key Strategic Moves and Developments

    • 7.4. NuMedii Inc.

      • 7.4.1. Company Overview

      • 7.4.2. Key Executives

      • 7.4.3. Company Snapshot

      • 7.4.4. Operating Business Segments

      • 7.4.5. Product Portfolio

      • 7.4.6. Business Performance

      • 7.4.7. Key Strategic Moves and Developments

    • 7.5. Recursion Pharmaceuticals Inc.

      • 7.5.1. Company Overview

      • 7.5.2. Key Executives

      • 7.5.3. Company Snapshot

      • 7.5.4. Operating Business Segments

      • 7.5.5. Product Portfolio

      • 7.5.6. Business Performance

      • 7.5.7. Key Strategic Moves and Developments

    • 7.6. SOM Innovation Biotech S.L.

      • 7.6.1. Company Overview

      • 7.6.2. Key Executives

      • 7.6.3. Company Snapshot

      • 7.6.4. Operating Business Segments

      • 7.6.5. Product Portfolio

      • 7.6.6. Business Performance

      • 7.6.7. Key Strategic Moves and Developments

    • 7.7. Sosei Group Corporation (SoseiHeptares)

      • 7.7.1. Company Overview

      • 7.7.2. Key Executives

      • 7.7.3. Company Snapshot

      • 7.7.4. Operating Business Segments

      • 7.7.5. Product Portfolio

      • 7.7.6. Business Performance

      • 7.7.7. Key Strategic Moves and Developments

    • 7.8. Exscientia Limited

      • 7.8.1. Company Overview

      • 7.8.2. Key Executives

      • 7.8.3. Company Snapshot

      • 7.8.4. Operating Business Segments

      • 7.8.5. Product Portfolio

      • 7.8.6. Business Performance

      • 7.8.7. Key Strategic Moves and Developments

    • 7.9. Healx

      • 7.9.1. Company Overview

      • 7.9.2. Key Executives

      • 7.9.3. Company Snapshot

      • 7.9.4. Operating Business Segments

      • 7.9.5. Product Portfolio

      • 7.9.6. Business Performance

      • 7.9.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL DRUG REPURPOSING MARKET FOR ONCOLOGY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL DRUG REPURPOSING MARKET FOR CNS DISORDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL DRUG REPURPOSING MARKET FOR NEURODEGENERATIVE DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL DRUG REPURPOSING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL DRUG REPURPOSING MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. NORTH AMERICA DRUG REPURPOSING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. NORTH AMERICA DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 9. U.S. DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 10. CANADA DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 11. MEXICO DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 12. EUROPE DRUG REPURPOSING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. EUROPE DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 14. FRANCE DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 15. GERMANY DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 16. ITALY DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 17. SPAIN DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 18. UK DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 19. RUSSIA DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 20. REST OF EUROPE DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 21. ASIA-PACIFIC DRUG REPURPOSING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 22. ASIA-PACIFIC DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 23. CHINA DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 24. JAPAN DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 25. INDIA DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 26. SOUTH KOREA DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 27. AUSTRALIA DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 28. THAILAND DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 29. MALAYSIA DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 30. INDONESIA DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 31. REST OF ASIA PACIFIC DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 32. LAMEA DRUG REPURPOSING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 33. LAMEA DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 34. BRAZIL DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 35. SOUTH AFRICA DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 36. SAUDI ARABIA DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 37. UAE DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 38. ARGENTINA DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 39. REST OF LAMEA DRUG REPURPOSING, BY THERAPEUTIC AREA, 2022-2032 ($MILLION)
  • TABLE 40. ATOMWISE INC.: KEY EXECUTIVES
  • TABLE 41. ATOMWISE INC.: COMPANY SNAPSHOT
  • TABLE 42. ATOMWISE INC.: OPERATING SEGMENTS
  • TABLE 43. ATOMWISE INC.: PRODUCT PORTFOLIO
  • TABLE 44. ATOMWISE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 45. BIOVISTA INC.: KEY EXECUTIVES
  • TABLE 46. BIOVISTA INC.: COMPANY SNAPSHOT
  • TABLE 47. BIOVISTA INC.: OPERATING SEGMENTS
  • TABLE 48. BIOVISTA INC.: PRODUCT PORTFOLIO
  • TABLE 49. BIOVISTA INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 50. CENTENE CORPORATION (HEALTH NET LLC): KEY EXECUTIVES
  • TABLE 51. CENTENE CORPORATION (HEALTH NET LLC): COMPANY SNAPSHOT
  • TABLE 52. CENTENE CORPORATION (HEALTH NET LLC): OPERATING SEGMENTS
  • TABLE 53. CENTENE CORPORATION (HEALTH NET LLC): PRODUCT PORTFOLIO
  • TABLE 54. CENTENE CORPORATION (HEALTH NET LLC): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 55. NUMEDII INC.: KEY EXECUTIVES
  • TABLE 56. NUMEDII INC.: COMPANY SNAPSHOT
  • TABLE 57. NUMEDII INC.: OPERATING SEGMENTS
  • TABLE 58. NUMEDII INC.: PRODUCT PORTFOLIO
  • TABLE 59. NUMEDII INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 60. RECURSION PHARMACEUTICALS INC.: KEY EXECUTIVES
  • TABLE 61. RECURSION PHARMACEUTICALS INC.: COMPANY SNAPSHOT
  • TABLE 62. RECURSION PHARMACEUTICALS INC.: OPERATING SEGMENTS
  • TABLE 63. RECURSION PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
  • TABLE 64. RECURSION PHARMACEUTICALS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 65. SOM INNOVATION BIOTECH S.L.: KEY EXECUTIVES
  • TABLE 66. SOM INNOVATION BIOTECH S.L.: COMPANY SNAPSHOT
  • TABLE 67. SOM INNOVATION BIOTECH S.L.: OPERATING SEGMENTS
  • TABLE 68. SOM INNOVATION BIOTECH S.L.: PRODUCT PORTFOLIO
  • TABLE 69. SOM INNOVATION BIOTECH S.L.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 70. SOSEI GROUP CORPORATION (SOSEIHEPTARES): KEY EXECUTIVES
  • TABLE 71. SOSEI GROUP CORPORATION (SOSEIHEPTARES): COMPANY SNAPSHOT
  • TABLE 72. SOSEI GROUP CORPORATION (SOSEIHEPTARES): OPERATING SEGMENTS
  • TABLE 73. SOSEI GROUP CORPORATION (SOSEIHEPTARES): PRODUCT PORTFOLIO
  • TABLE 74. SOSEI GROUP CORPORATION (SOSEIHEPTARES): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 75. EXSCIENTIA LIMITED: KEY EXECUTIVES
  • TABLE 76. EXSCIENTIA LIMITED: COMPANY SNAPSHOT
  • TABLE 77. EXSCIENTIA LIMITED: OPERATING SEGMENTS
  • TABLE 78. EXSCIENTIA LIMITED: PRODUCT PORTFOLIO
  • TABLE 79. EXSCIENTIA LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 80. HEALX: KEY EXECUTIVES
  • TABLE 81. HEALX: COMPANY SNAPSHOT
  • TABLE 82. HEALX: OPERATING SEGMENTS
  • TABLE 83. HEALX: PRODUCT PORTFOLIO
  • TABLE 84. HEALX: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG REPURPOSING MARKET SEGMENTATION
  • FIGURE 2. GLOBAL DRUG REPURPOSING MARKET
  • FIGURE 3. SEGMENTATION DRUG REPURPOSING MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN DRUG REPURPOSING MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALDRUG REPURPOSING MARKET
  • FIGURE 11. DRUG REPURPOSING MARKET SEGMENTATION, BY BY THERAPEUTIC AREA
  • FIGURE 12. DRUG REPURPOSING MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. DRUG REPURPOSING MARKET FOR CNS DISORDERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. DRUG REPURPOSING MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. DRUG REPURPOSING MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 17. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 18. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 19. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 20. COMPETITIVE DASHBOARD
  • FIGURE 21. COMPETITIVE HEATMAP: DRUG REPURPOSING MARKET
  • FIGURE 22. Top player positioning, 2022
  • FIGURE 23. ATOMWISE INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 24. ATOMWISE INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 25. ATOMWISE INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 26. BIOVISTA INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 27. BIOVISTA INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 28. BIOVISTA INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 29. CENTENE CORPORATION (HEALTH NET LLC): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 30. CENTENE CORPORATION (HEALTH NET LLC): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 31. CENTENE CORPORATION (HEALTH NET LLC): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 32. NUMEDII INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 33. NUMEDII INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 34. NUMEDII INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 35. RECURSION PHARMACEUTICALS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 36. RECURSION PHARMACEUTICALS INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 37. RECURSION PHARMACEUTICALS INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 38. SOM INNOVATION BIOTECH S.L.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. SOM INNOVATION BIOTECH S.L.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 40. SOM INNOVATION BIOTECH S.L.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 41. SOSEI GROUP CORPORATION (SOSEIHEPTARES): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 42. SOSEI GROUP CORPORATION (SOSEIHEPTARES): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 43. SOSEI GROUP CORPORATION (SOSEIHEPTARES): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 44. EXSCIENTIA LIMITED: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. EXSCIENTIA LIMITED: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 46. EXSCIENTIA LIMITED: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 47. HEALX: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. HEALX: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 49. HEALX: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Drug Repurposing Market

Start reading.
This Report and over 66,804+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers